A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors
Repertoire Immune Medicines
Summary
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria * Histologically or cytologically confirmed locally advanced or metastatic solid tumors that is not amenable to curative treatment. * At least one measurable lesion per RECIST v1.1 as assessed by the investigator. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ function as defined in the trial protocol. * Ability to provide written informed consent and comply with trial procedures. Exclusion Criteria: * History of another malignancy within 3 years before the first dose of trial intervention, with the exception of malignancies con…
Interventions
- DrugRPTR-1-201
RPTR-1-201
- DrugPD-1 / PD-L1 monoclonal antibody
PD-1/PD-L1 monoclonal antibody
Location
- START MidwestGrand Rapids, Michigan